首页|甘精胰岛素结合格列美脲治疗2型糖尿病对患者不良反应的影响

甘精胰岛素结合格列美脲治疗2型糖尿病对患者不良反应的影响

Effect of Insulin Glargine Combined with Glimepiride on Adverse Reac-tions in Patients with Type 2 Diabetes Mellitus

扫码查看
目的 探讨甘精胰岛素结合格列美脲治疗2型糖尿病对患者不良反应的影响.方法 选取2020年12月—2023年8月福建省三明市宁化县总医院收治的120例2型糖尿病患者作为研究对象,用随机数表法分为对照组和研究组,各60例,对照组使用甘精胰岛素,研究组在对照组基础上加入格列美脲治疗,对比两组患者的治疗效果、不良反应、血糖水平和胰岛功能指标.结果 治疗后,研究组治疗总有效率高于对照组,不良反应发生率低于对照组,差异有统计学意义(P均<0.05).治疗后,研究组糖化血红蛋白、餐后2 h血糖、空腹血糖水平均低于对照组,胰岛β细胞功能指数、胰岛素抵抗指数高于对照组,差异有统计学意义(P均<0.05).结论 甘精胰岛素结合格列美脲的应用效果好,可降低血糖指标,不良反应较小.
Objective To investigate the effect of insulin glargine combined with glimepiride on adverse reactions in patients with type 2 diabetes.Methods A total of 120 patients with type 2 diabetes admitted to Ninghua County Gen-eral Hospital,Sanming City,Fujian Province from December 2020 to August 2023 were selected as the study objects.They were divided into control group and study group by random number table method,with 60 cases in each group.The control group received insulin glargine and the study group was treated with glimepiide based on the control group.Results After treatment,the total effective rate of the study group was higher than that of the control group,and the incidence of adverse reactions was lower than that of the control group,and the differences were statistically sig-nificant(both P<0.05).After treatment,glycated haemoglobin A1c,2 hours postprandial blood glucose and fasting blood glucose in the study group were lower than those in the control group,and homeostasis model assessment-β and homeostasis model assessment-insulin resistance were higher than those in the control group,the differences were sta-tistically significant(all P<0.05).Conclusion The application effect of insulin glargine combined with glimepiride is good,it can reduce the blood glucose index and with less adverse reaction.

Insulin glargineGlimepirideCombined therapyType 2 diabetesAdverse reactionsTherapeutic effect

王泽文、李科怡、张利红

展开 >

福建省三明市宁化县总医院感染科,福建三明 365400

甘精胰岛素 格列美脲 结合治疗 2型糖尿病 不良反应 治疗效果

2024

糖尿病新世界
中国病理生理学会

糖尿病新世界

影响因子:0.461
ISSN:1672-4062
年,卷(期):2024.27(3)
  • 15